Connor, Clark & Lunn Investment Management Ltd. Kal Vista Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 22,949 shares of KALV stock, worth $191,853. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,949
Previous 10,704
114.4%
Holding current value
$191,853
Previous $126,000
110.32%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding KALV
# of Institutions
125Shares Held
47.8MCall Options Held
551KPut Options Held
110K-
Vr Adviser, LLC New York, NY6.25MShares$52.2 Million7.5% of portfolio
-
Tang Capital Management LLC San Diego, CA4.32MShares$36.1 Million4.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.21MShares$35.2 Million1.92% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$33.4 Million3.51% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$30.8 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $206M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...